Asia-Pacific Melanoma Cancer Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Asia-Pacific Melanoma Cancer Diagnostics Market Size

• The Asia-Pacific melanoma cancer diagnostics market size was valued at USD 694.93 million in 2024 and is expected to reach USD 1,315.13 million by 2032, at a CAGR of 8.3% during the forecast period
• The market growth is largely driven by increasing awareness about early detection, rising prevalence of melanoma cases, and advancements in diagnostic technologies such as molecular testing, imaging, and AI-assisted analysis
• Furthermore, growing investments in healthcare infrastructure, government initiatives for cancer screening programs, and the rising demand for accurate and timely diagnostic solutions are establishing advanced melanoma diagnostics as the preferred choice in clinical settings. These converging factors are accelerating the adoption of innovative diagnostic methods, thereby significantly boosting the industry's growth

Asia-Pacific Melanoma Cancer Diagnostics Market Analysis

• Melanoma cancer diagnostics, including biomarker tests, imaging, biopsy, and AI-assisted analysis, are becoming essential components of modern oncology care in both clinical and research settings due to their accuracy, early detection capabilities, and integration with digital health platforms
• The escalating demand for melanoma diagnostics is primarily fueled by rising incidence of skin cancer, growing awareness about early detection, and an increasing preference for precise, timely, and patient-friendly diagnostic solutions
• Australia dominated the Asia-Pacific melanoma cancer diagnostics market with the largest revenue share of 39.5% in 2024, characterized by advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and strong government-led skin cancer screening programs, with hospitals and specialized diagnostic centers witnessing substantial growth in advanced testing
• China is expected to be the fastest-growing country in the Asia-Pacific melanoma cancer diagnostics market during the forecast period due to rising healthcare investments, expanding diagnostic facilities, and increasing awareness campaigns
• Biomarker tests segment dominated the melanoma cancer diagnostics market with a market share of 42% in 2024, driven by their high accuracy, ability to detect genetic mutations, and growing adoption for personalized treatment planning in clinical settings

Report Scope and Asia-Pacific Melanoma Cancer Diagnostics Market Segmentation

Asia-Pacific Melanoma Cancer Diagnostics Market Trends

Advancement in AI-Assisted and Digital Diagnostics

• A significant and accelerating trend in the Asia-Pacific melanoma cancer diagnostics market is the increasing integration of artificial intelligence (AI) and digital pathology platforms with traditional diagnostic methods such as dermoscopy, imaging, and biopsy. This fusion of technologies is enhancing diagnostic accuracy, speed, and patient outcomes
  • For instance, AI-enabled dermoscopy tools in Australia analyze skin lesions using machine learning algorithms, helping dermatologists detect melanoma at an earlier stage with higher precision. Similarly, digital pathology platforms in China allow pathologists to review biopsy slides remotely, facilitating faster diagnosis
• AI integration enables features such as automated lesion detection, predictive analytics for high-risk patients, and real-time diagnostic suggestions. For instance, some systems can track lesion progression over time and alert clinicians to abnormal changes, improving clinical decision-making
• The seamless integration of AI and digital diagnostics with hospital information systems allows centralized management of patient data, streamlining workflows and enabling telemedicine consultations across regions
• This trend towards more intelligent, precise, and interconnected diagnostic systems is fundamentally reshaping clinical expectations for melanoma care. Consequently, companies such as DermTech and MoleMap are developing AI-enabled platforms that combine imaging and biomarker analysis to support early and accurate diagnosis
• The demand for melanoma diagnostics that offer AI integration and digital reporting capabilities is growing rapidly across both hospitals and specialized diagnostic centers, as healthcare providers increasingly prioritize speed, accuracy, and patient-centric care

Asia-Pacific Melanoma Cancer Diagnostics Market Dynamics

Driver

Rising Prevalence of Skin Cancer and Early Detection Programs

• The increasing incidence of melanoma in countries such as Australia, China, and Japan, coupled with government-led skin cancer screening initiatives, is a significant driver for the heightened demand for advanced diagnostics
  • For instance, in March 2024, the Australian Department of Health expanded its national skin cancer screening program, encouraging hospitals and diagnostic centers to adopt AI-assisted and biomarker-based diagnostic tools. Such initiatives by key healthcare authorities are expected to drive market growth during the forecast period
• As awareness of early detection benefits rises, melanoma diagnostics provide high-accuracy identification of lesions and enable timely treatment decisions, offering a compelling alternative to conventional visual inspection methods
• Furthermore, increasing adoption of digital health technologies and telemedicine platforms is making advanced diagnostics more accessible, allowing clinicians to monitor high-risk patients remotely and integrate results into comprehensive care plans
• Government support for early detection programs, coupled with the growing preference for personalized and timely diagnostic solutions, is driving adoption in both hospital networks and specialized diagnostic laboratories

Restraint/Challenge

High Cost and Regulatory Compliance Hurdles

• Concerns surrounding the high cost of advanced diagnostic platforms, including AI-assisted imaging and biomarker tests, pose a significant challenge to broader adoption, particularly in developing countries where budget constraints exist
  • For instance, high upfront costs for AI-enabled dermoscopy systems have limited their use in smaller clinics or rural diagnostic centers, restricting overall market penetration
• Addressing regulatory compliance and obtaining approvals from national health authorities is also critical, as strict guidelines for diagnostic accuracy and patient safety can delay product launch and adoption. Companies such as DermTech emphasize clinical validation and compliance with regulatory standards to reassure healthcare providers
• While costs are gradually decreasing with technological advancements, the perceived premium for advanced diagnostics compared to traditional methods can hinder adoption, especially among price-sensitive healthcare providers
• Overcoming these challenges through cost-effective diagnostic solutions, streamlined regulatory approvals, and targeted clinician education will be vital for sustained growth in the Asia-Pacific melanoma cancer diagnostics market

Asia-Pacific Melanoma Cancer Diagnostics Market Scope

The market is segmented on the basis of product type, test type, end user, and distribution channel.

• By Product Type

On the basis of product type, the melanoma cancer diagnostics market is segmented into instruments, consumables and accessories, and others. The instruments segment dominated the market with the largest revenue share of 45.2% in 2024, driven by the increasing adoption of advanced diagnostic equipment such as dermatoscopes, imaging systems, and automated biopsy instruments. Hospitals and specialized diagnostic centers often prioritize instruments for their precision, reliability, and ability to support multiple types of diagnostic tests. The market also sees strong demand for instruments due to their long-term utility, ease of integration with digital platforms, and compatibility with AI-assisted diagnostic tools. Regular upgrades in instrument technology and growing investments in healthcare infrastructure further sustain this segment's dominance.

The consumables and accessories segment is expected to witness the fastest growth from 2025 to 2032, fueled by recurring demand for reagents, slides, kits, and other consumables essential for biomarker, imaging, and biopsy tests. Rising patient volumes, expanding screening programs, and the growing prevalence of melanoma across Asia-Pacific are driving consistent consumption of these products. Consumables are critical for maintaining test accuracy, and manufacturers are increasingly innovating cost-effective and high-performance kits to support growing diagnostic needs.

• By Test Type

On the basis of test type, the melanoma cancer diagnostics market is segmented into biomarker tests, imaging tests, biopsy, FISH tests, CGH tests, IHC tests, and others. The biomarker tests segment dominated the market with a revenue share of 42% in 2024, driven by their ability to detect genetic mutations and guide personalized treatment strategies. Hospitals and diagnostic laboratories prioritize biomarker tests due to their high accuracy, clinical relevance, and ability to complement other diagnostic methods such as imaging and biopsy. The growing awareness of personalized medicine and early detection of melanoma has further reinforced the demand for biomarker-based diagnostics. In addition, ongoing R&D and technological innovations have enhanced test sensitivity and turnaround time, strengthening the segment's position.

The imaging tests segment is expected to witness the fastest growth from 2025 to 2032, fueled by increasing adoption of AI-assisted dermoscopy and digital imaging solutions across hospitals and specialized centers. Imaging tests allow non-invasive, rapid detection of suspicious lesions and are increasingly integrated with telemedicine platforms. Rising investments in modern imaging equipment and awareness campaigns highlighting early detection benefits contribute to strong growth. Imaging also supports large-scale screening programs, making it a preferred choice in urban and semi-urban regions.

• By End User

On the basis of end user, the melanoma cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others. The hospitals segment dominated the market with a share of 44.8% in 2024, due to well-established infrastructure, high patient volumes, and the ability to implement advanced diagnostics at scale. Hospitals often integrate multiple testing methods including biomarker analysis, imaging, and biopsy, offering comprehensive care under one roof. They also benefit from government initiatives promoting skin cancer screening and early detection. Strong relationships with diagnostic equipment manufacturers and ongoing staff training programs further reinforce hospital dominance.

The independent diagnostic laboratories segment is expected to witness the fastest growth from 2025 to 2032, fueled by the rising number of specialized laboratories catering to urban and semi-urban populations. These labs provide flexible, cost-effective, and rapid testing solutions for melanoma diagnostics. The increasing availability of AI-assisted platforms and remote reporting tools allows these laboratories to expand their service offerings, attract more patients, and collaborate with hospitals and research institutes for advanced testing programs.

• By Distribution Channel

On the basis of distribution channel, the melanoma cancer diagnostics market is segmented into direct tender and retail sales. The direct tender segment dominated the market with a share of 52.3% in 2024, driven by bulk procurement of diagnostic instruments, consumables, and test kits by hospitals, government screening programs, and cancer research institutes. Direct tender contracts often include long-term supply agreements and technical support, making them the preferred mode of procurement for large healthcare facilities. Strong relationships with manufacturers and consistent demand for high-quality diagnostic solutions reinforce dominance in this segment.

The retail sales segment is expected to witness the fastest growth from 2025 to 2032, fueled by rising demand from smaller clinics, independent laboratories, and diagnostic centers in urban and semi-urban areas. Retail sales allow flexible purchase quantities, quick replenishment of consumables, and access to the latest diagnostic kits and instruments. Growing awareness among clinicians and patients, coupled with the increasing number of diagnostic facilities, is driving steady adoption of retail distribution models across the Asia-Pacific region.

Asia-Pacific Melanoma Cancer Diagnostics Market Regional Analysis

• Australia dominated the Asia-Pacific melanoma cancer diagnostics market with the largest revenue share of 39.5% in 2024, characterized by advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and strong government-led skin cancer screening programs, with hospitals and specialized diagnostic centers witnessing substantial growth in advanced testing
• Healthcare providers in the region highly value the accuracy, early detection capabilities, and integration of melanoma diagnostics with digital health platforms, enabling improved patient outcomes and personalized treatment planning
• This widespread adoption is further supported by strong government initiatives, high awareness of melanoma risks, and the growing preference for AI-assisted and biomarker-based diagnostic solutions, establishing advanced melanoma diagnostics as the preferred choice for hospitals, specialized labs, and research centers

The Australia Melanoma Cancer Diagnostics Market Insight

The Australia melanoma cancer diagnostics market captured the largest revenue share of 39.5% in 2024, fueled by advanced healthcare infrastructure, high awareness of skin cancer risks, and government-led national screening programs. Healthcare providers increasingly prioritize early detection through biomarker tests, imaging, and AI-assisted diagnostics to improve patient outcomes. The growing adoption of digital health platforms and telemedicine further supports market expansion, making Australia a key leader in melanoma diagnostics across the Asia-Pacific region.

China Melanoma Cancer Diagnostics Market Insight

The China melanoma cancer diagnostics market is poised to grow at the fastest CAGR during the forecast period, driven by rising healthcare investments, expanding diagnostic infrastructure, and increasing awareness of early detection benefits. Urbanization and growing disposable incomes support the adoption of advanced diagnostic solutions, while AI-enabled imaging and biomarker-based diagnostics are increasingly integrated into hospitals and specialized laboratories.

Japan Melanoma Cancer Diagnostics Market Insight

The Japan melanoma cancer diagnostics market is gaining momentum due to high technological adoption in healthcare, an aging population, and emphasis on preventive care. Hospitals and research institutes are adopting AI-assisted dermoscopy and digital pathology platforms to enhance early detection and treatment planning. Integration with electronic health records and telemedicine platforms is further fueling the demand for advanced melanoma diagnostics in both residential and commercial healthcare settings.

India Melanoma Cancer Diagnostics Market Insight

The India melanoma cancer diagnostics market accounted for a significant revenue share in Asia-Pacific in 2024, attributed to rapid urbanization, growing awareness of skin cancer, and increasing investments in healthcare infrastructure. Rising adoption of advanced diagnostic tools in hospitals, independent laboratories, and cancer research institutes is driving growth. Government initiatives supporting early detection, along with the availability of cost-effective biomarker and imaging tests, are expanding access to melanoma diagnostics across urban and semi-urban regions.

South Korea Melanoma Cancer Diagnostics Market Insight

The South Korea melanoma cancer diagnostics market is expected to expand at a substantial CAGR during the forecast period, fueled by strong government support for cancer prevention, advanced healthcare facilities, and high adoption of digital health solutions. Hospitals and diagnostic centers increasingly leverage AI-assisted imaging, biomarker tests, and biopsy technologies to improve diagnostic accuracy. Public awareness campaigns and integration with telemedicine platforms further enhance early detection efforts.

Asia-Pacific Melanoma Cancer Diagnostics Market Share

The Asia-Pacific melanoma cancer diagnostics industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Agilent Technologies, Inc. (U.S.)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• AMLo Biosciences Limited (U.K.)
• Myriad Genetics, Inc. (U.S.)
• Castle Biosciences, Inc. (U.S.)
• DermTech, (U.S.)
• Damae Medical (France)
• DermLite (U.S.)
• DermaSensor, Inc. (U.S.)
• Skyline Dx (Netherlands)
• Neracare Inc. (U.S.)
• VERISKIN INC. (U.S.)
• Illumina, Inc. (U.S.)

What are the Recent Developments in Asia-Pacific Melanoma Cancer Diagnostics Market?

• In March 2025, the iToBoS project introduced an AI-powered full-body scanner capable of detecting early-stage skin cancers, including melanoma. The device scans the entire body in six minutes, providing risk assessments for each skin anomaly
• In January 2025, the Asia-Pacific Journal of Oncology published a review article on the emergence of liquid biopsy as a new diagnostic and prognostic tool for cancer. The article highlighted the advantages of this non-invasive method, which relies on body fluids to identify biomarkers for cancer, over traditional, more intrusive tissue biopsies. This indicates the increasing adoption and research into liquid biopsy for melanoma in the region
• In June 2024, the University of Queensland launched a nearly USD 3 million research initiative to utilize artificial intelligence (AI) and 3D skin imaging for early melanoma diagnosis. The project aims to establish the world's largest skin-imaging database, enhancing access to diagnostic services in regional areas of Australia. This initiative seeks to reduce detection-to-treatment time, ultimately saving lives in underserved communities
• In April 2023, PHC Corporation, based in Tokyo, Japan, announced a collaboration with NovaScan, Inc. to explore the feasibility of a new investigational medical device called MarginScan. This device is designed to support physicians in detecting non-melanoma skin cancer and aims to provide real-time margin detection during surgery. This partnership demonstrates a focus on improving diagnostic tools for a broader range of skin cancers in the Asia-Pacific market
• In January 2021, Fujifilm India, in a joint venture with Dr. Kutty's Healthcare, launched a medical screening center called NURA in Bangalore. The center provides AI-enabled imaging services for the early detection of various cancers, including skin cancer. This initiative is part of a trend to expand advanced diagnostic services to meet the growing demand in a country with a high population and significant healthcare needs

SKU-69562